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• The impact of the e4 allele on memory and 
visuospatial ability over time may be strong 
in people who show early cognitive decline, 
independent of age, sex and education.
• Hippocampal volume loss is greater in 
people who carry the e4 allele independent 
of covariates. 
• It is unclear if plasma biomarkers reflect 
brain pathology.
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• Alzheimer’s Disease is a form of dementia 
characterized by loss of memory, cognitive 
dysfunction, and changes in brain 
physiology.
• Literature suggests that age, the presence 
of the APOE e4 gene and an MCI diagnosis 
are the three strongest risk factors for the 
development of Alzheimer’s Disease. 
• Research Problem: Little research has 
been done regarding an accessible 
diagnosis, and therapy or drug target for 
Alzheimer’s Disease. Furthermore, the 
longitudinal progression of AD has not been 
fully modeled. 
• Research Question: How can changes in 
memory, visuospatial ability, the amyloid β 
42/40 ratio, and the total hippocampal 
volume be used to accurately predict the 
onset and progression of Alzheimer’s 
disease?
• Hypothesis: Based on previous research, 
we hypothesize that memory, visuospatial 
ability, and the total hippocampal volume will 
decrease, and the amyloid β 42/40 ratio will 
change significantly. 
• Data from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI database) 
were analyzed.
• Divided participants into four categories 
based on genetic risk (e4 carrier or e2/e3 
alleles only) and stable diagnosis 
(cognitively normal or MCI): nl_e23 (normal 
noncarrier), nl_e4, mci_e23, and mci_e4.
• Three primary data types were analyzed: 
1. Cognitive function (memory and 
visuospatial tests)
2. Plasma Aβ42/40
3. Hippocampal volume (through MRI)
• JASP, Python, and R were used to complete 
statistical testing (a repeated measures 
ANOVA) and data visualization.
• Sex, age, and level of education were used 
as covariates.
• Participants: 174
• Average Age: 77.99
• Our data lacks sufficient information regarding 
underrepresented racial and ethnic groups, as well 
as non-English speakers
• ADNI’s data from prior studies were heavily 
focused on the Caucasian population in the United 
States, making it difficult to observe a wider range 
of data regarding other races and ethnicities
Figure 1. After controlling for age, sex, and education, the 
difference between individuals with MCI (n=68), scored lower
compared to normal individuals (n=103), p < 0.001. The interaction 
between diagnosis and risk group was also significant (p = 0.002);  
as the MCI e4 carriers did worse than MCI non-carriers, although 
no genetic component was observed for normal individuals.
Figure 2. After controlling for age, sex, and education, 
cognitively normal individuals (n=106)  score higher than 
individuals diagnosed with MCI (n=68), p= 0.049. The 
interaction between diagnosis and risk group was also 
significant (p=0.009). Individuals with an MCI diagnosis 
carrying the e4 gene (n=30) experience a drop in visuospatial 
ability in month 24, much earlier than other groups.
Figure 3. After controlling for age, sex, and education, cognitively 
normal individuals (n=106) have a higher amyloid β 42/40 ratio 
than individuals diagnosed with MCI (n=68), p = 0.041. However, 
this difference diminishes over time (p=0.045).
Figure 4. After controlling for age, sex, and education, the total 
hippocampal volume of e4 carriers (n=63) is greater than that for 
noncarriers (n=111), p < 0.001. The effect is also significant over 
time (p = 0.023), with greater hippocampal volume loss in e4 
carriers, most prominent at the 36-month timepoint.
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Figure 5. Hippocampus Structure
Figure 6. Normal brain (left) and Alzheimer’s 
affected brain (right) with evident neuronal 
damage
FUTURE GOALS
• In order to produce more inclusive results, 
data should be collected from a diverse, 
nation-wide range of racial and ethnic groups 
with varying backgrounds in terms of 
economic status, gender, and educational 
background.
• Future directions include gathering data from 
surrounding communities in order to yield a 
larger scope of data and produce equally 
comprehensive results that can be applied 
and benefit more individuals and doing 
outreach to discuss results with the local 
community. 
• Further directions include applying machine 
learning to provide a prediction and 
progression model for AD and expansion of 
the variable set to include more biomarkers. 
